Novel Combination Of Pozelimab And Cemdisiran (Poze-Cemdi) Achieved Greater Control Of Intravascular Hemolysis In Patients With Paroxysmal Nocturnal Hemoglobinuria Compared To Ravulizumab
Novel Combination Of Pozelimab And Cemdisiran (Poze-Cemdi) Achieved Greater Control Of Intravascular Hemolysis In Patients With Paroxysmal Nocturnal Hemoglobinuria Compared To Ravulizumab . (MENAFN - GlobeNewsWire - Nasdaq)   Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108967505/Novel-Combination-Of-Pozelimab-And-Cemdisiran-Poze-Cemdi-Achieved-Greater-Control-Of-Intravascular-Hemolysis-In-Patients-With-Paroxysmal-Nocturnal-Hemoglobinuria-Compared-To-Ravulizumab
2024-12-07
rss
(MENAFN - GlobeNewsWire - Nasdaq)   Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease ...
Novel Combination Of Pozelimab And Cemdisiran (Poze-Cemdi) Achieved Greater Control Of Intravascular Hemolysis In Patients With Paroxysmal Nocturnal Hemoglobinuria Compared To Ravulizumab